MedTrace Logo

Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)

NCT00867828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2011-10-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of NKO™ softgels in reducing decline of global cognitive function as measured by the Neuropsychological Test Battery (NTB), in patients diagnosed with early stage Alzheimer's disease when compared to fish oil and a placebo after 24 weeks of treatment.

Conditions

  • Early Onset Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Neptune Krill Oil

Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.

DIETARY_SUPPLEMENT

Fish Oil

Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.

DIETARY_SUPPLEMENT

Placebo (soy oil)

Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.

Sponsors & Collaborators

  • Neptune Technologies and Bioressources Inc.

    collaborator INDUSTRY

  • NeuroBioPharm Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-07-31
Completion
2011-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867828 on ClinicalTrials.gov